**Company Profile**

**Industry Sector:** Life sciences/Healthcare

**Company Overview:** 490 BioTech develops patent protected light-emitting (autoboluminescent) human cell lines genetically programmed to 'report' on biological events or interactions that affect their metabolic status in real time. Incorporation of these cell lines into *in vitro* cell culture screening and *in vivo* small animal preclinical efficacy/toxicity testing models accelerates the pace of new drug discovery and moves drugs more rapidly and more effectively towards Phase I human testing with a reduced overall cost. Their autobioluminescence also makes them ideal for use in diagnostic assays, as R&D molecular biology tools, and for environmental monitoring.

**Target Market(s):** Pharmaceutical/Biotech industries, contract research organizations, academic/government researchers, *in vitro/in vivo* preclinical imaging, ADME-Tox assays, high-throughput drug discovery, human cell lines, stem cell lines, cloning vectors

**Key Value Drivers**

**Technology:** A synthetically designed luciferase system that enables cells and tissues to autonomously express bioluminescence either continuously or in response to metabolic or environmental signals.

**Competitive Advantage:** 490 BioTech's autobioluminescent imaging technology eliminates the costly and error-prone addition of a chemical substrate (i.e., luciferin) that is required for all other bioluminescent imaging technologies. We provide more data, faster, at a lower cost.

**Plan & Strategy:** 490 BioTech is developing an inventory of autobioluminescent human cell lines, cloning vectors, and assay platforms designed to meet the high-throughput *in vivo/in vitro* screening needs of our core pharma/biotech market. We are seeking product distributors and technology development partners.

*NIH NIEHS Grant number 2R44ES022567-02

**Management**

**Leadership:**
- Gary Sayler, Ph.D., CEO – Pioneered the application of substrate-free autobioluminescence with over 25 years of bioimaging expertise
- Steven Ripp, Ph.D., COO – 16 years of experience in autobioluminescence applications across multiple industry sectors
- Dan Close, Ph.D., Chief Scientific Officer – Designed, developed, and validated autobioluminescence technology in human cell lines
- Dan Morrison, MBA, Business Development Officer – Productive business leader with a strong record of successful corporate management and new business start-up experience.

**Product Pipeline**

**Existing products:**
1. Cloning vectors; enables customers to integrate 490 BioTech's autobioluminescent expression technology into their desired cell lines
2. Autobioluminescent human cell lines; pre-made, ready-to-use autobioluminescent human cell lines
3. Autobioluminescent yeast screening kits; rapid chemical estrogen and androgen disruptor activity monitoring
4. Custom design of autobioluminescent human cell lines; contract research service to customers

**Pipeline products:**
1. Autobioluminescent human stem cells
2. 3-Dimensional autobioluminescent tissue scaffolds
3. Autobioluminescent zebrafish